Opendata, web and dolomites

AmInnovation SIGNED

Disruptive Innovation to Treat Alzheimer’s and Parkinson’s diseases: new target, new patented drug, new therapeutic strategy.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 AmInnovation project word cloud

Explore the words cloud of the AmInnovation project. It provides you a very rough idea of what is the project "AmInnovation" about.

financial    disruptive    people    neurodegenerative    fact    code    inventors    membrane    wrong    brain    patent    artificial    biological    rely    demonstrated    international    amyloid    conclusive    academic    diseases    owned    scientific    2018    neurological    quite    linking    overcome    optimizing    direct    clinical    oligomers    disorders    century    trials    worldwide    double    solution    responsible    amypore    parkinson    culprits    intelligence    unsuccessful    tests    license    pores    2050    calcium    candidate    administer    immunotherapies    global    totally    plan    firstly    cells    cure    paradigm    strategies    exclusive    protein    plaques    paradigms    additional    alzheimer    first    pathologies    correlation    neurosciences    disease    anti    incriminate    revolutions    progression    oligomer    counts    action    terrible    symptoms    publications    mechanisms    social    cascade    position    overdose    advantages    linked    amyp53    block    21st    medical    innovation    drug    molecular    million    secondly    stop    relying    world    neurotoxic   

Project "AmInnovation" data sheet

The following table provides information about the project.

Coordinator
AMYPORE 

Organization address
address: BOULEVARD ELIE CORRADI 51
city: SEPTEMES-LES-VALLONS
postcode: 13240
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Project website http://www.amypore.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AMYPORE FR (SEPTEMES-LES-VALLONS) coordinator 50˙000.00

Map

 Project objective

Neurodegenerative disorders represent the most important medical, social and financial challenges for the 21st century. In 2018, the world counts 50 million people with Alzheimer’s disease and 7 million with Parkinson’s disease, and the number of cases will double before 2050. The current medical paradigms, which incriminate amyloid plaques as the main culprits of these pathologies, do not provide a cure or even stop the progression of the diseases. All clinical trials based on anti-plaques immunotherapies have been unsuccessful. The reason for this global failure is quite simple: these strategies are based on the wrong targets. Indeed, there is no correlation at all between the neurological symptoms and the presence of amyloid plaques in the brain. Thus, the paradigm linking amyloid plaques to neurodegenerative diseases has been totally wrong.

AmyPore action plan has been totally different from these unsuccessful approaches. Firstly, we rely on top-level academic researchers who identified the real molecular mechanisms that are the direct cause of the diseases: the amyloid protein oligomers which are responsible for an overdose of calcium in brain cells (amyloid pores). Secondly, AmyPore has taken advantages of the recent artificial intelligence revolutions in neurosciences for identifying a new biological code and optimizing the design of AmyPore lead product candidate.

AmyPore solution, called “AmyP53” is the disruptive innovation that has demonstrated to be in the position to overcome these terrible diseases. As a matter of fact, relying upon : - an exclusive license, linked to an international patent owned by the inventors, - recent scientific publications, - and additional recent conclusive tests,

AmyP53 is : - easy to test, - easy to produce worldwide, - easy to administer.

AmyP53 is not only one of the first drug that targets the oligomer cascade, it is the only one that can block the formation neurotoxic oligomers in the membrane of brain cells.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "AMINNOVATION" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "AMINNOVATION" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

TAPPXSSAI (2019)

Development of a system for automatic ad insertion into on-demand streaming video to provide new monetization mechanisms to the media industry

Read More  

Skye (2018)

Redefining Drone Safety and Autonomous Operation for Indoor Commercial Applications

Read More  

Osto.Me (2020)

Ostomy Market Disruption: First Leak Proof Ostomy Appliance removing the need for Accessories in the Ostomy Market

Read More